Related Experiment Videos
Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits
Abstract:
To investigate the therapeutic potential of mitomycin C (MMC) in the management of proliferative vitreoretinopathy (PVR), antiproliferative effect of MMC on rabbit retinal pigment epithelial (RPE) cells, its intraocular toxicity, and its preventive effect on experimental PVR were investigated. Cultured rabbit RPE cells were exposed to various concentrations of MMC ranging from 1.0 x 10(-3) to 1.0 microgram/ml for 72 hours. The RPE cells were then cultured in a medium without MMC for another 7 days, and the cells were harvested and counted. Toxicity of MMC to rabbit retina was evaluated after intravitreal injection of MMC by means of clinical observation, electrophysiologic test, and histopathologic examination. To test antiproliferative effect of MMC on experimental PVR, 200,000 cultured RPE cells were injected into the vitreous cavity of pigmented rabbits, and either 0.2 micrograms or 1.0 micrograms MMC was injected intravitreally 24 hours after RPE cell injection. Two to four weeks later, the vitreoretinal status was compared between MMC-treated eyes and control eyes. The antiproliferative effect of MMC on RPE cells was evident at the concentration of 1.0 x 10(-2) micrograms/ml. The drug concentration required for 50% inhibition of growth was 3 x 10(-2) micrograms/ml. Nontoxic intraocular doses of MMC were 2.0 micrograms in rabbit eyes with normal vitreous and 1.0 microgram in rabbit eyes with gas-compressed vitreous. The rates of traction retinal detachment after intravitreal RPE cell injection were reduced in the eyes treated with MMC compared with control eyes. These results indicate that MMC may have clinical application to the treatment of PVR.
Insights
Mitomycin C (MMC) shows therapeutic potential for proliferative vitreoretinopathy (PVR). This study found MMC effectively inhibits retinal pigment epithelial (RPE) cell proliferation and reduces PVR in experimental models without significant intraocular toxicity.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Proliferative vitreoretinopathy (PVR) is a major cause of vision loss following retinal detachment.
- Current treatments for PVR have limitations, necessitating the exploration of novel therapeutic agents.
Purpose of the Study:
- To evaluate the therapeutic potential of mitomycin C (MMC) for managing proliferative vitreoretinopathy (PVR).
- To assess the antiproliferative effects of MMC on rabbit retinal pigment epithelial (RPE) cells.
- To determine the intraocular toxicity and preventive efficacy of MMC in experimental PVR.
Main Methods:
- Rabbit RPE cells were exposed to varying MMC concentrations to assess antiproliferative effects.
- Intraocular toxicity was evaluated through clinical, electrophysiologic, and histopathologic examinations after intravitreal MMC injection.
- Experimental PVR was induced by injecting RPE cells into rabbit vitreous, followed by intravitreal MMC administration to assess preventive effects.
Main Results:
- Mitomycin C demonstrated significant antiproliferative effects on RPE cells at concentrations as low as 1.0 x 10(-2) micrograms/ml.
- The 50% inhibitory concentration (IC50) for RPE cell growth was determined to be 3 x 10(-2) micrograms/ml.
- Nontoxic intraocular doses were established, and MMC treatment reduced the incidence of traction retinal detachment in experimental PVR models.
Conclusions:
- Mitomycin C exhibits potent antiproliferative activity against RPE cells.
- MMC demonstrates a favorable safety profile at therapeutic doses, with manageable intraocular toxicity.
- These findings suggest that mitomycin C holds promise as a clinical treatment for proliferative vitreoretinopathy.